ClinicalTrials.gov
public full text
Public Domain
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer#828565
- RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)#1125943
- A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer#803294
- Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.#876986
- A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients#1138072
Record · ID 881512
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive